Mirum Pharmaceuticals (Nasdaq: MIRM) posts 2025 sales update, new deck

Rhea-AI Filing Summary

Mirum Pharmaceuticals furnished a current report describing new investor information. The company issued a press release with preliminary unaudited net product sales for the year ended December 31, 2025, including sales for its liver disease medicines LIVMARLI (maralixibat), CHOLBAM and CTEXLI, along with preliminary unaudited cash, cash equivalents and investments.

Mirum also posted an updated corporate slide presentation on its website in connection with the J.P. Morgan Healthcare Conference, and furnished this presentation as an exhibit. Both the press release and the investor presentation are being furnished rather than filed, which means they are not automatically incorporated into other SEC reports unless specifically referenced.

false000175942500017594252026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________________________________

FORM 8-K

____________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

____________________________________________________

Mirum Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

____________________________________________________

Delaware			001-38981			83-1281555
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California						94404
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 667-4085

N/A

(Former Name or Former Address, if Changed Since Last Report)

____________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

MIRM

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release announcing, among other things, the Company's preliminary unaudited net product sales for the fiscal year ended December 31, 2025, preliminary unaudited net product sales of LIVMARLI (maralixibat) and CHOLBAM and CTEXLI, and preliminary unaudited cash, cash equivalents and investments. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the “Investors” portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release dated January 12, 2026
99.2						Investor Presentation dated January 12, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Mirum Pharmaceuticals, Inc.
Date: January 12, 2026			By:			/s/ Christopher Peetz
						Christopher Peetz
						Chief Executive Officer

FAQ

What did Mirum Pharmaceuticals (MIRM) disclose in this 8-K?

Mirum Pharmaceuticals reported that it released a press release with preliminary unaudited net product sales for 2025, including key liver disease drugs, and furnished this information to investors.

Which products are included in Mirum Pharmaceuticals’ preliminary 2025 sales update?

The preliminary unaudited net product sales update covers LIVMARLI (maralixibat), CHOLBAM and CTEXLI.

Did Mirum Pharmaceuticals (MIRM) provide any balance sheet information?

Yes. Mirum reported preliminary unaudited figures for cash, cash equivalents and investments as part of its press release.

What investor materials did Mirum Pharmaceuticals release with this filing?

The company furnished a press release as Exhibit 99.1 and an investor presentation as Exhibit 99.2, both dated January 12, 2026.

Where can investors find Mirum Pharmaceuticals’ updated presentation?

Mirum stated that the corporate slide presentation is available in the “Investors” section of its website at www.mirumpharma.com and is also furnished as Exhibit 99.2.

Are Mirum Pharmaceuticals’ exhibits considered filed with the SEC?

No. The company specified that the information, including Exhibits 99.1 and 99.2, is furnished, not filed, and is not subject to certain Exchange Act liabilities unless later incorporated by reference.